Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Postoperative Adjuvant Therapy With Recombinant Interferon-Alpha Following Curative Resection of Hepatocellular Carcinoma
NCT00234182Phase 2Completed
- Sponsor
- The University of Hong Kong
- Start
- Jan 2000
- Modality
- Cytokines & Interferons
01
Overview
Phase 2, randomised, open-label trial of interferon alfa-2b in hepatocellular carcinoma (HCC) (3 arms), sponsored by The University of Hong Kong. Primary endpoint: Occurrence of recurrent disease. Started Jan 2000; status: completed.
02
Drugs
interferon alfa-2b
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00234182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00234182.